MA29330B1 - Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires. - Google Patents
Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.Info
- Publication number
- MA29330B1 MA29330B1 MA30215A MA30215A MA29330B1 MA 29330 B1 MA29330 B1 MA 29330B1 MA 30215 A MA30215 A MA 30215A MA 30215 A MA30215 A MA 30215A MA 29330 B1 MA29330 B1 MA 29330B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- receptor antagonists
- inflammatory diseases
- pgd2 receptor
- pgd2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
CETTE INVENTION RENVOIE AUX INHIBITEURS DE CRTH2 REPRÉSENTÉS PAR LA FORMULE STRUCTURELLE (I). L¿INVENTION CONCERNE LES VALEURS POUR LES VARIABLES DE LA FORMULE STRUCTURELLE (I).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65592705P | 2005-02-24 | 2005-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29330B1 true MA29330B1 (fr) | 2008-03-03 |
Family
ID=36593677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30215A MA29330B1 (fr) | 2005-02-24 | 2007-09-11 | Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires. |
Country Status (26)
Country | Link |
---|---|
US (1) | US7951950B2 (fr) |
EP (1) | EP1861372A1 (fr) |
JP (1) | JP2008543726A (fr) |
KR (1) | KR20070114762A (fr) |
CN (1) | CN101146776A (fr) |
AR (1) | AR052580A1 (fr) |
AU (1) | AU2006216713A1 (fr) |
BR (1) | BRPI0608553A2 (fr) |
CA (1) | CA2598133A1 (fr) |
CR (1) | CR9378A (fr) |
DO (1) | DOP2006000054A (fr) |
GT (1) | GT200600093A (fr) |
IL (1) | IL185422A0 (fr) |
MA (1) | MA29330B1 (fr) |
MX (1) | MX2007010215A (fr) |
NI (1) | NI200700221A (fr) |
NO (1) | NO20074388L (fr) |
PE (1) | PE20061013A1 (fr) |
RU (1) | RU2007135224A (fr) |
SV (1) | SV2007002429A (fr) |
TN (1) | TNSN07325A1 (fr) |
TW (1) | TW200640869A (fr) |
UA (1) | UA90706C2 (fr) |
UY (1) | UY29397A1 (fr) |
WO (1) | WO2006091674A1 (fr) |
ZA (1) | ZA200707498B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITVA20050050A1 (it) * | 2005-08-05 | 2007-02-06 | Lamberti Spa | Sistemi fotopolimerizzabili contenenti coiniziatori fotoreticolabili a bassa estraibilita' e volatilita' |
US20100015085A1 (en) * | 2006-05-01 | 2010-01-21 | Johns Hopkins University | Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress |
SI2327693T1 (sl) | 2007-12-14 | 2012-09-28 | Pulmagen Therapeutics Asthma Ltd Fulmer Hal Windmil Road | Indoli in njihova terapevtska raba |
ES2386948T3 (es) | 2008-07-15 | 2012-09-07 | F. Hoffmann-La Roche Ag | Ácidos aminotetrahidroindazoloacéticos |
EP2307382B1 (fr) | 2008-07-15 | 2011-12-21 | F. Hoffmann-La Roche AG | Acides aminotétrahydroindazoloacétiques |
CA2734104A1 (fr) | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Aminotetralines substituees |
WO2010018113A2 (fr) | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Bi-aryle aminotétralines |
CA2739725A1 (fr) | 2008-11-17 | 2010-05-20 | F. Hoffmann-La Roche Ag | Acides naphtylacetiques employes en tant qu'antagonistes ou agonistes partiels de crth2 |
RU2011124149A (ru) | 2008-11-17 | 2012-12-27 | Ф.Хоффманн-Ля Рош Аг | Нафтилуксусные кислоты |
NZ591914A (en) | 2008-11-17 | 2013-04-26 | Hoffmann La Roche | Naphthylacetic acids |
BR112013000254A2 (pt) | 2010-07-05 | 2016-05-24 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 |
EP2457900A1 (fr) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2 |
EP2526945A1 (fr) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Nouveaux antagonistes de CRTH2 |
MX2013014900A (es) * | 2011-06-17 | 2014-02-17 | Merck Sharp & Dohme | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2. |
EP2548863A1 (fr) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | Nouveaux antagonistes de CRTH2 |
EP2548876A1 (fr) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | Nouveaux antagonistes de CRTH2 |
US8470884B2 (en) | 2011-11-09 | 2013-06-25 | Hoffmann-La Roche Inc. | Alkenyl naphthylacetic acids |
US8691993B2 (en) * | 2011-12-12 | 2014-04-08 | Hoffmann-La Roche Inc. | Piperidinyl naphthylacetic acids |
WO2013088109A1 (fr) | 2011-12-16 | 2013-06-20 | Oxagen Limited | Combinaison d'un antagoniste de crth2 et d'un inhibiteur de pompe à protons pour le traitement de l'œsophagite à éosinophiles |
MX2014007688A (es) | 2011-12-21 | 2014-07-28 | Actelion Pharmaceuticals Ltd | Derivados de heterociclilo y su uso como moduladores del receptor d2 de prostaglandina. |
EP2847181A1 (fr) * | 2012-05-11 | 2015-03-18 | AbbVie Inc. | Dérivés de pyridazine et pyridine en tant qu'inhibiteurs de nampt |
WO2013170118A1 (fr) * | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Dérivés de thiazolecarboxamide utiles en tant qu'inhibiteurs de la nampt |
US9296723B2 (en) | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
WO2014006585A1 (fr) | 2012-07-05 | 2014-01-09 | Actelion Pharmaceuticals Ltd | Dérivés hétérocyclylés 1-phényl-substitués et leur utilisation en tant que modulateurs du récepteur de la prostaglandine d2 |
WO2015074081A1 (fr) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Compositions de benzopipérazine en tant qu'inhibiteurs de bromodomaines bet |
LT3071203T (lt) | 2013-11-18 | 2021-05-25 | Forma Therapeutics, Inc. | Tetrahidrochinolino kompozicijos kaip bet bromodomeno inhibitoriai |
US9727784B2 (en) * | 2014-06-03 | 2017-08-08 | Digitalglobe, Inc. | Some automated and semi-automated tools for linear feature extraction in two and three dimensions |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
DK0450097T3 (da) | 1989-10-20 | 1996-05-20 | Otsuka Pharma Co Ltd | Benzoheterocykliske forbindelser |
CA2116334A1 (fr) | 1992-07-02 | 1994-01-20 | Hidenori Ogawa | Antagoniste de l'oxytocine |
MY125037A (en) * | 1998-06-10 | 2006-07-31 | Glaxo Wellcome Spa | 1,2,3,4 tetrahydroquinoline derivatives |
JP2002521441A (ja) | 1998-07-28 | 2002-07-16 | スミスクライン・ビーチャム・コーポレイション | Ccr5モジュレーターとしてのプロペンアミド |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6147089A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6048873A (en) * | 1998-10-01 | 2000-04-11 | Allergan Sales, Inc. | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
KR100826485B1 (ko) | 1999-10-14 | 2008-05-02 | 가켄 세야쿠 가부시키가이샤 | 테트라히드로퀴놀린 유도체 |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
JP2003519221A (ja) | 2000-01-03 | 2003-06-17 | ファルマシア コーポレイション | シクロオキシゲナーゼ−2−媒介障害を治療するためのジヒドロベンゾピラン、ジヒドロベンゾチオピラン及びテトラヒドロキノリン |
DE10005302A1 (de) | 2000-02-07 | 2002-01-17 | Gruenenthal Gmbh | Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate |
EP1283055A4 (fr) | 2000-04-07 | 2003-05-07 | Takeda Chemical Industries Ltd | Promoteurs solubles de secretion du precurseur de la proteine beta-amyoide |
US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
JP2002053557A (ja) | 2000-08-14 | 2002-02-19 | Japan Tobacco Inc | アポリポ蛋白a−i産生促進薬 |
US6313107B1 (en) * | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
US6291677B1 (en) * | 2000-08-29 | 2001-09-18 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
AU2001286471B2 (en) | 2000-08-29 | 2006-09-07 | Allergan, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
EP1325914A4 (fr) | 2000-09-14 | 2004-11-17 | Kaken Pharma Co Ltd | Composes de tetrahydroquinoline |
DE10103657A1 (de) | 2001-01-27 | 2002-08-01 | Henkel Kgaa | Neue Kupplerkomponente für Oxidationsmittel |
SE0101161D0 (sv) | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
DK1425270T3 (da) | 2001-04-30 | 2006-07-03 | Pfizer Prod Inc | Fremgangsmåder og intermediater til fremstilling af 4-aminoquinolin CETP inhibitorer |
AU2003231513A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Pgd2 receptor antagonist |
EP2423190A1 (fr) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Composés présentant un antagonisme du récepteur PGD 2 |
US20050228016A1 (en) | 2002-06-13 | 2005-10-13 | Enrique Michelotti | Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex |
JP2006508077A (ja) * | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのpgd2レセプタアンタゴニスト |
US7504508B2 (en) * | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
EP1413306A1 (fr) * | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Dérivé de la tétrahydroquinoline en tant qu'antagonistes de CRTH2 |
JP2006511486A (ja) | 2002-10-21 | 2006-04-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Crth2拮抗剤としてのテトラヒドロキノリン誘導体 |
JPWO2004052863A1 (ja) | 2002-12-06 | 2006-04-13 | 協和醗酵工業株式会社 | 抗炎症剤 |
EP1435356A1 (fr) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Dérivés de la quinoléine en tant qu'antagonistes de CRTH2 |
BRPI0408897A (pt) * | 2003-03-28 | 2006-04-18 | Pfizer Prod Inc | derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade |
US20050038070A1 (en) | 2003-07-09 | 2005-02-17 | Amgen Inc. | Asthma and allergic inflammation modulators |
UA84749C2 (ru) | 2004-04-07 | 2008-11-25 | Милленниум Фармасьютикалз, Инк. | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
-
2006
- 2006-02-23 AU AU2006216713A patent/AU2006216713A1/en not_active Withdrawn
- 2006-02-23 UA UAA200710441A patent/UA90706C2/ru unknown
- 2006-02-23 RU RU2007135224/04A patent/RU2007135224A/ru not_active Application Discontinuation
- 2006-02-23 EP EP06735798A patent/EP1861372A1/fr not_active Withdrawn
- 2006-02-23 CN CNA2006800096718A patent/CN101146776A/zh active Pending
- 2006-02-23 MX MX2007010215A patent/MX2007010215A/es not_active Application Discontinuation
- 2006-02-23 KR KR1020077021757A patent/KR20070114762A/ko not_active Application Discontinuation
- 2006-02-23 GT GT200600093A patent/GT200600093A/es unknown
- 2006-02-23 JP JP2007557128A patent/JP2008543726A/ja active Pending
- 2006-02-23 WO PCT/US2006/006287 patent/WO2006091674A1/fr active Application Filing
- 2006-02-23 BR BRPI0608553-9A patent/BRPI0608553A2/pt not_active IP Right Cessation
- 2006-02-23 CA CA002598133A patent/CA2598133A1/fr not_active Abandoned
- 2006-02-23 US US11/360,885 patent/US7951950B2/en active Active
- 2006-02-23 ZA ZA200707498A patent/ZA200707498B/xx unknown
- 2006-02-24 PE PE2006000220A patent/PE20061013A1/es not_active Application Discontinuation
- 2006-02-24 TW TW095106336A patent/TW200640869A/zh unknown
- 2006-02-24 DO DO2006000054A patent/DOP2006000054A/es unknown
- 2006-02-24 UY UY29397A patent/UY29397A1/es not_active Application Discontinuation
- 2006-02-24 AR ARP060100701A patent/AR052580A1/es unknown
- 2006-02-24 SV SV2006002429A patent/SV2007002429A/es unknown
-
2007
- 2007-08-21 IL IL185422A patent/IL185422A0/en unknown
- 2007-08-23 NI NI200700221A patent/NI200700221A/es unknown
- 2007-08-24 TN TNP2007000325A patent/TNSN07325A1/en unknown
- 2007-08-29 NO NO20074388A patent/NO20074388L/no not_active Application Discontinuation
- 2007-09-11 MA MA30215A patent/MA29330B1/fr unknown
- 2007-09-12 CR CR9378A patent/CR9378A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101146776A (zh) | 2008-03-19 |
BRPI0608553A2 (pt) | 2010-01-12 |
TNSN07325A1 (en) | 2008-12-31 |
MX2007010215A (es) | 2007-11-07 |
TW200640869A (en) | 2006-12-01 |
AU2006216713A1 (en) | 2006-08-31 |
PE20061013A1 (es) | 2006-10-13 |
JP2008543726A (ja) | 2008-12-04 |
IL185422A0 (en) | 2008-01-06 |
NI200700221A (es) | 2008-05-09 |
WO2006091674A1 (fr) | 2006-08-31 |
AR052580A1 (es) | 2007-03-21 |
KR20070114762A (ko) | 2007-12-04 |
EP1861372A1 (fr) | 2007-12-05 |
UA90706C2 (ru) | 2010-05-25 |
US7951950B2 (en) | 2011-05-31 |
US20060241109A1 (en) | 2006-10-26 |
NO20074388L (no) | 2007-11-20 |
UY29397A1 (es) | 2006-10-02 |
ZA200707498B (en) | 2008-11-26 |
RU2007135224A (ru) | 2009-03-27 |
DOP2006000054A (es) | 2006-08-31 |
CA2598133A1 (fr) | 2006-08-31 |
CR9378A (es) | 2008-01-21 |
GT200600093A (es) | 2006-10-19 |
SV2007002429A (es) | 2007-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29330B1 (fr) | Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires. | |
TW200736247A (en) | Compounds for the treatment of inflammatory disorders | |
TW200736248A (en) | Compounds for the treatment of inflammatory disorders | |
MA32351B1 (fr) | Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer | |
EA200870292A1 (ru) | Соединения на основе имидазола, композиции, содержащие их, и способы их применения | |
ATE538099T1 (de) | 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden | |
MA30053B1 (fr) | Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires . | |
EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
MX2012010404A (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de enfermedades. | |
EA201290894A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 | |
TW200612911A (en) | Compounds for the treatment of inflammatory disorders | |
MA32594B1 (fr) | Amidophenoxyindazoles utiles comme inhibiteurs du c-met | |
EA201070535A1 (ru) | Новые агонисты глюкокортикоидных рецепторов | |
MA33826B1 (fr) | Analogue du peptide d'oxyntomoduline | |
EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
DE60214990D1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
MA30798B1 (fr) | Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1 | |
ATE495171T1 (de) | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors | |
BRPI0518690A2 (pt) | tratamento de doenÇa inflamatària do intestino | |
MA34098B1 (fr) | Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs | |
ATE540038T1 (de) | Heterocyclen als proteinkinaseinhibitoren | |
DE602004025586D1 (de) | Alpha-aminoamid derivate zur verwendung als anti-inflammatorische wirkstoffe | |
EA201170783A1 (ru) | Новые соединения | |
ATE514679T1 (de) | Biarylcarboxyarylamide als modulatoren des vanilloid-1-rezeptors |